Does inverse planning improve plan quality in interstitial high-dose-rate breast brachytherapy?

high-dose-rate interstitial breast implants inverse planning

Journal

Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 21 01 2020
accepted: 12 03 2020
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 13 5 2020
Statut: ppublish

Résumé

To investigate the effect of input parameters for an inverse optimization algorithm, and dosimetrically evaluate and compare clinical treatment plans made by inverse and forward planning in high-dose-rate interstitial breast implants. By using a representative breast implant, input parameters responsible for target coverage and dose homogeneity were changed step-by-step, and their optimal values were determined. Then, effects of parameters on dosimetry of normal tissue and organs at risk were investigated. The role of dwell time modulation restriction was also studied. With optimal input parameters, treatment plans of forty-two patients were re-calculated using an inverse optimization algorithm (HIPO). Then, a pair-wise comparison between forward and inverse plans was performed using dose-volume parameters. To find a compromise between target coverage and dose homogeneity, we recommend using weight factors in the range of 70-90 for minimum dose, and in the range of 10-30 for maximum dose. Maximum dose value of 120% with a weight factor of 5 is recommended for normal tissue. Dose constraints for organs at risk did not play an important role, and the dwell time gradient restriction had only minor effect on target dosimetry. In clinical treatment plans, at identical target coverage, the inverse planning significantly increased the dose conformality (COIN, 0.75 vs. 0.69, By using appropriate input parameters, inverse planning can provide dosimetrically superior dose distributions over forward planning in interstitial breast implants.

Identifiants

pubmed: 32395141
doi: 10.5114/jcb.2020.94584
pii: 40413
pmc: PMC7207228
doi:

Types de publication

Journal Article

Langues

eng

Pagination

166-174

Informations de copyright

Copyright © 2020 Termedia.

Déclaration de conflit d'intérêts

The authors report no conflict of interest.

Références

J Contemp Brachytherapy. 2015 Jan;6(4):362-70
pubmed: 25834580
Lancet. 2016 Jan 16;387(10015):229-38
pubmed: 26494415
Radiother Oncol. 2016 Jan;118(1):199-204
pubmed: 26776444
PLoS One. 2018 Oct 4;13(10):e0205229
pubmed: 30286187
Phys Med Biol. 2015 Jan 21;60(2):537-48
pubmed: 25549084
Med Phys. 2001 May;28(5):773-9
pubmed: 11393472
J Contemp Brachytherapy. 2010 Dec;2(4):163-170
pubmed: 27853479
Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):365-9
pubmed: 26549994
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):515-24
pubmed: 9457842
Med Dosim. 2015 Autumn;40(3):235-9
pubmed: 25795565
J Med Radiat Sci. 2015 Jun;62(2):168-74
pubmed: 26229683
J Contemp Brachytherapy. 2019 Aug;11(4):349-355
pubmed: 31523236
Brachytherapy. 2011 Sep-Oct;10(5):421-6
pubmed: 21353647
Radiother Oncol. 2013 Aug;108(2):197-202
pubmed: 23742961
J Appl Clin Med Phys. 2013 Jul 08;14(4):4198
pubmed: 23835384
Brachytherapy. 2018 May - Jun;17(3):615-620
pubmed: 29396035
Phys Med Biol. 2016 Feb 7;61(3):1155-70
pubmed: 26760757
Brachytherapy. 2014 May-Jun;13(3):250-6
pubmed: 24613132
Radiother Oncol. 2010 Dec;97(3):501-6
pubmed: 20846734
J Contemp Brachytherapy. 2010 Sep;2(3):117-128
pubmed: 27853473
Radiother Oncol. 2010 Mar;94(3):264-73
pubmed: 20181402
Phys Med. 2017 Dec;44:58-65
pubmed: 29254592
Radiother Oncol. 2010 Mar;94(3):274-9
pubmed: 20181401
J Contemp Brachytherapy. 2019 Aug;11(4):379-383
pubmed: 31523240
Brachytherapy. 2016 Jan-Feb;15(1):102-11
pubmed: 26561276
Anticancer Res. 2015 Nov;35(11):6091-6
pubmed: 26504034
J Contemp Brachytherapy. 2017 Feb;9(1):89-98
pubmed: 28344609
J Contemp Brachytherapy. 2019 Jun;11(3):256-266
pubmed: 31435433
Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):801-8
pubmed: 10386636
Radiother Oncol. 2009 Nov;93(2):331-40
pubmed: 19846230
Strahlenther Onkol. 2019 Nov;195(11):991-1000
pubmed: 31482321
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):820-7
pubmed: 18455325
Australas Phys Eng Sci Med. 2015 Mar;38(1):55-61
pubmed: 25481387
J Contemp Brachytherapy. 2015 Dec;7(6):479-84
pubmed: 26816505

Auteurs

Tibor Major (T)

Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary.
Department of Oncology, Semmelweis University, Budapest, Hungary.

Georgina Fröhlich (G)

Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary.
Eötvös Loránd University, Faculty of Science, Budapest, Hungary.

Norbert Mészáros (N)

Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary.
Department of Oncology, Semmelweis University, Budapest, Hungary.

Viktor Smanykó (V)

Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary.

Csaba Polgár (C)

Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary.
Department of Oncology, Semmelweis University, Budapest, Hungary.

Classifications MeSH